Kodiak Sciences (NASDAQ:KOD) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Kodiak Sciences to reach your target.
Hmm, we can't give any reliable projection for Kodiak Sciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| KOD Price (Kodiak Sciences stock price per share) |
$97.90 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Biotechnology stocks | |
| Free Cash Flow Jitter | 40% |
No open-market insider buys or sells are recorded in the six months to 2026-11-20.
The six months before that had 2 buys and 0 sales.
Open-market buys and sells reported by Kodiak Sciences's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-18 | BAKER BROS. ADVISORS LP | Buy | 217,428 | $23.00 |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Buy | 2,391,268 | $23.00 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 8,115,058 shares shorted. With 39,130,931 shares available for purchase and an average trading volume over the past 10 trading days of 863,090, it would take at least 9.4 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Net income was negative in all 10 fiscal years from 2016 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$982 million over those years, against net income of -$1,534 million.
In 2025, net income was -$230 million and operating cash flow was -$136 million, so no ratio is shown for that year.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2016 | -17.1 | -16 | 0.8 | n/a |
| 2017 | -27.9 | -17.7 | 0.2 | n/a |
| 2018 | -41.4 | -29 | 0.1 | n/a |
| 2019 | -47.4 | -39.1 | 0.4 | n/a |
| 2020 | -133 | -83.4 | 3.8 | n/a |
| 2021 | -267 | -182 | 17 | n/a |
| 2022 | -334 | -206 | 37 | n/a |
| 2023 | -260 | -154 | 41.4 | n/a |
| 2024 | -176 | -117 | 0.4 | n/a |
| 2025 | -230 | -136 | 0.5 | n/a |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $210 million against total liabilities of $194 million, or 108.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 55.2% of total assets in 2025, compared with 2218.9% in 2017, a decrease of 2163.7 percentage points.
Stockholders equity was $157 million in 2025, up from negative equity of -$68.7 million in 2017.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -161.5% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2017 | 3.2 | 1.4 | 72 | -68.7 |
| 2018 | 92.2 | 88.3 | 5.4 | 86.8 |
| 2019 | 359 | 212 | 13.5 | 345 |
| 2020 | 1,067 | 944 | 207 | 861 |
| 2021 | 904 | 732 | 241 | 663 |
| 2022 | 667 | 190 | 230 | 436 |
| 2023 | 479 | 286 | 214 | 266 |
| 2024 | 336 | 168 | 185 | 150 |
| 2025 | 352 | 210 | 194 | 157 |
Free cash flow was negative in every one of the 10 fiscal years we have for Kodiak Sciences under its current filer.
We do not estimate a fair value for Kodiak Sciences while its free cash flow growth is not positive, so there is no value comparison here.
Year-to-year variability in free cash flow is volatile, measured at 40%.
We do not have a dividend yield for Kodiak Sciences.
These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Biotechnology industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Biotechnology industry, the ones closest in market capitalization to Kodiak Sciences, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Kodiak Sciences (KOD) | 6,402 | - | - | - | - |
| Repligen Corporation (RGEN) | 10,886 | - | - | - | 417% above |
| Bio-Techne Corporation (TECH) | 11,420 | 66.7 | 0.3% | 1.4% | 91% above |
| Neurocrine Biosciences (NBIX) | 15,850 | 23.2 | - | - | 491% above |
| Biogen (BIIB) | 36,531 | 107.0 | - | 10.1% | 69% below |
| Amgen (AMGN) | 237,363 | 25.4 | 2.2% | 4.4% | 11% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1468748.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: KOD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Kodiak Sciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to KOD: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
Gold-Silver Ratio Today: Chart and Average
What Happened to the Stock Market Today?
How to Make Money with Penny Stocks
When is the Right Time to Buy a Stock?
Always Choose Employer Matching 401k Contributions
What Does COVID-19 Mean for Stocks?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data